Full name
A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)
NCT Number
NCT06537414
Geography
Non-US
Locations
TBD
Primary Endpoints
- Number of participants achieving functional cure. Up to 100 Weeks
External Link
https://clinicaltrials.gov/study/NCT06537414
Order
7
Disease
Version
Phase
2b